Paragon 28 (ZBH) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $189M

Market Cap: $15.9BFounded: 2010HQ: Englewood, United States

Sector Ranking#4 in Regenerative Medicine

Overview

Founded in 2010, Paragon 28 rapidly grew by focusing exclusively on the underserved foot and ankle surgical market, developing a comprehensive portfolio of trauma, bunion, fusion, biologic, and wound care solutions. Its strategic acquisition by Zimmer Biomet in late 2024 for ~$450 million has positioned it to leverage global scale while maintaining its focused brand and innovation culture. The company's future strategy hinges on integrating its SMART28™ digital surgery platform with Zimmer Biomet's resources to drive procedural standardization and data-driven improvements in patient outcomes.

OrthopedicsFoot & Ankle Surgery

Technology Platform

Dual-platform strategy combining comprehensive physical implant systems (trauma, bunion, fusion, biologics) with the SMART28™ digital surgery ecosystem for AI-powered planning and data analytics.

Funding History

3

Total raised:$189M

IPO$144MUndisclosedOct 28, 2021

Series B$30MUndisclosedJun 15, 2020

Series A$15MUndisclosedJun 15, 2018

Opportunities

The high-growth foot and ankle market, driven by demographics and a shift to minimally invasive surgery, presents a major expansion opportunity.

Leveraging Zimmer Biomet's global distribution can accelerate international sales.

The SMART28™ digital platform offers a path to higher-margin, recurring revenue and ecosystem lock-in through data-driven surgical tools.

Risk Factors

Integration risks with Zimmer Biomet could dilute the entrepreneurial culture critical to innovation.

Intense competition from both large ortho giants and focused rivals threatens market share.

Successful adoption of the SMART28™ digital platform is not guaranteed and faces hurdles in surgeon workflow integration and proving clinical utility.

Competitive Landscape

Competes against large diversified players (Stryker, J&J) and focused specialists (Treace Medical, Arthrex). Its advantage lies in pure-play focus, comprehensive procedural systems, and post-acquisition backing from Zimmer Biomet, which provides scale and resources while aiming to preserve its innovative, surgeon-centric culture.